May 30, 2026 — RNews

#disability progression — Saturday, May 30, 2026 (1 items)

hot top new

← prev day next day →

0

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. (linkinghub.elsevier.com)

Giovannoni G … Oh J The Lancet 2026-05-30

#clinical trial #immunotherapy #multiple sclerosis #disability progression